Investigation of Detected by Recent Various Human Papillomavirus from General Hospital in Seoul Area

Jun-Beom Lee¹,², Chang-Eun Park²,³

¹Department of Pathology, Gangnam CHA Hospital, Seoul 06135, Korea
²Graduate School of Biomedical Laboratory Science, Namseoul University, Cheonan 31020, Korea
³Department of Biomedical Laboratory Science, Molecular Diagnostics Research Institute, Namseoul University, Cheonan 31020, Korea

Human papillomavirus (HPV) infection is a necessary precondition of cervical cancer. A change from cytology to molecular HPV testing is, however, challenging. A new HPV DNA chip test for the infection of 22 HPV genotypes were developed in Korea. The purpose of this study was to investigate the prevalence and genotype distribution of HPV infection in the Seoul area. Over the last year, a total of 5,614 samples were tested. Using a chip test, HPV genotypes were detected in 1,596 (28.4%); of which, 679 (42.5%) were considered as high risk and low risk HPV were 152 (9.5%). 831 were single positive samples (n=1596). The most frequently found genotypes in all HPV-single positive samples (n=831) were HPV-16 (16.5%), 58 (15.2%), 52 (8.8%), 51 (7.1%) and 56 (5.9%). Mixed genotypes (n=219) were detected in 2 (n=176, 11.0%), 3 (n=37, 5.9%), and 4 (n=2, 0.1%) positive samples (n=1596). This study demonstrated that epidemiologic investigated HPV infection in patients of general hospital. These findings could be used to indicate a nationwide distribution of HPV and the adoption of vaccines. It is hoped that additional epidemiological research regarding the outcomes that are important to decision makers will be conducted.

Key words: DNA Chip, Genotype, Human papillomavirus.

Introduction

Human papillomavirus (HPV) is the causative agent for cervical cancer [1]. The cervical cancer screening was once a simple annual Pap smear. But recently used to the various sample preparation with ThinPrep, cervical brushing, formalin fixed tissue. In general, fourteen HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) are considered pathogenic or “high-risk (HR)” for causing the development of cervical cancer [2]. Cytology-based cervical cancer screening was introduced decades ago and subsequently implemented in many industrialized countries. A virus genome exists inside the capsid, and harbors eight partially overlapping open reading frames. The HPV gene structure is being three regions: an early region (E), late region (L), and a long control region (LCR) [3].
Cervical intraepithelial neoplasia (CIN) is a premalignant lesion and divided into three stages (1, 2, and 3). It is estimated that, in 70% of affected women, CIN 2~3 was progress to cervical cancer after 10~20 years [4].

Generally screening techniques for HPV were widely used to cervical lesions by cervical smear or visual inspection used to screen women. These tests can be used alone or in a sequence (e.g. HPV test followed by a cervical smear when HPV positive) [5]. Recently, HPV genotyping using a reverse blot hybridization assay (REBA) in atypical squamous cells of undetermined significance (ASCUS) cytology samples. Therefore, the REBA test is a useful method to detect HR-HPV genotypes [6,7]. In 2012, WHO committed to developing recommendations for screen-and-treat strategies to prevent cervical cancer and commissioned a series of reviews to inform those recommendations [8].

The E6 and E7 are oncoproteins that play a roles in cancer progression. The oncoprotein from E6 binds to p53, its can be the DNA repair, inhibits apoptosis, Oncoprotein E7 binds to retinoblastoma (Rb) protein, which is a well-known tumor suppressor, and promotes dysregulation of the cell cycle. Additionally, oncoprotein E7 also interacts with several cellular proteins other than Rb protein, and is involved in apoptosis inhibition [9,10].

Using a DNA chip test, we evaluated the clinical efficacy of HPV genotype based on cervical abnormalities. HPV genotyping using self-collected samples was feasible and well accepted, and showed sensitivity and specificity comparable to those achieved using clinician-collected samples [11].

Recent population-based studies in the United States have shown that 96% of cervical cancers, 93% of anal cancers, 64% of vaginal cancers, 51% of vulvar cancers, 36% of penile cancers, and 63% of oropharyngeal cancers are attributable to HPV [12]. Several screening methods focusing on the detection of HPV have emerged in recent years, as commercial assays that identify women who harbor cervical infections with at least one of 12~14 high-risk HPV (HR-HPV) types, which are associated with most cases of pre-invasive and cervical cancer.

In previous [13], the nested reverse transcription (RT) multiplex PCR protocol for the combined detection of E6/E7 mRNA of the 18 HPV types 6/11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56, 58, 59, 66 and 68. Also, researchers were demonstrated its potential as a sensitive diagnostic tool for cervical intraepithelial neoplasia (CIN) [14].

The Aptima HPV assay involves three consecutive steps, which take place in a single tube: target capture specimen processing; target amplification by transcription-mediated amplification (TMA) [15], and detection of the amplification products by the hybridization protection assay (HPA) [16]. The assay incorporates an internal control for nucleic acid capture, amplification, and detection, as well as operator or instrument error. After cell lysis the target mRNA is isolated from the specimen by sequence-specific capture oligomers that also contain a deoxyadenosine tail. Many reported that being performed to prevalence of HPV positive ratio, for preventing the development of cervical cancer [17-19].

We are showed that investigation of HPV genotype distribution with general hospital visitors in Seoul area, to guide HPV vaccine and randomized asymptomatic women.

Materials and Methods

1. Subjects

A total 5,614 including women participated in the present study covering the 2015 year. All cervical vaginal specimens came from woman who underwent routine physical examinations at the general hospital in Seoul area. None of the enrolled women had any previous history of HPV infection or any subjective symptoms for cervical diseases, the relevant subject characteristics of age distribution which ranged from 22 to 71 years. The study was approved by institutional review board at N University (NSU-1160428-01).

2. Sample collection

Cervical specimens were collected with a disposable cervical cell collector. The sampling head of the brush was placed into a 5 mL ThinPrep® PreservCyt solution vial (Hologic Inc., Marlborough, MA, USA) and kept at 4°C for no more than one week before DNA extraction. The samples were collected while the patients were counseling by instruction of medication. Sample types were cervical
brushing and ThinPrep.

3. HPV DNA extraction

Vaginal swab samples were collected and added to 5 mL of phosphate buffered saline (PBS) and vortexed vigorously to separate exfoliated cell from a cytobrush, followed by the removal of cytobrush. The cell suspensions were centrifuged for 5 min at 7,500 g and the cell pellet resuspended in 1 mL of PBS and transferred to a microcentrifuge tube for repeat centrifugation. The suspension was discarded and the pellet resuspended in 200 \( \mu L \) of PBS. DNA extraction was performed with a proteinase K (10 mg/mL). The extraction procedure was carried out according to the guidelines of the manufacturer. Purified DNAs were adjusted to 100 \( \mu L \) using a spin column and the DNA stored at \(-20^\circ C\).

4. PCR amplification

HPV detection and genotyping were performed by DNA amplification, flow-through hybridization and a gene chip using the HPV DNA chip kit (AGBIO Diagnostics Co., Chuncheon, Korea). Nested PCR was performed on a GeneAmp 9700 system (Thermo Fisher Scientific Inc., Waltham, MS, USA). The total volume for PCR was 25 \( \mu L \) containing 200 ng DNA. This assay can detect 15 HR-HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 69), and 6 low risk (LR) HPV genotypes (HPV 6, 11, 34, 40, 42, 43 and 44). The thermocycler was programmed as follows: 9 min at 94°C; 5 cycles of 1 min at 94°C, 2 min at 50°C, 30 sec at 72°C; 35 cycles of 1 min at 94°C, 2 min at 50°C, 15 sec at 72°C; and 2 min at 72°C. The isolation of DNA was evaluated with the amplification of \( \beta \)-globin. Negative and positive controls were performed at the end of each PCR assay. After PCR amplification, 5 \( \mu L \) of PCR aliquot was layered and electrophoresed on 2.5% agarose gels and stained with ethidium bromide.

5. DNA chip

The HPV Chip kit (AGBIO Diagnostics Co., Chuncheon, Korea), which is a PCR based DNA microarray system, was used for HPV genotyping. HPV chip for the detection of HPV genotypes has attained an approved license issued in accordance with biopharmaceuticals and medical devices from the Korean Food and Drug Administration (KFDA) in 2004 (approval of permission: KFDA 2004-07-20). The procedure of the experiment consists of hybridization, washing, scanning. Eighty \( \mu L \) of hybridization buffer was pre-heated at 40°C for 5 min. The PCR products (25 mL) were denatured at 95°C for 5 min. The mixed solution of premixture and hybridization buffer was put in the each hybridization well on the slide and sealed with cellophane tape to reduce evaporation. Hybridization was performed at 40°C for 30 min. To eliminate unbound probes, slides were washed twice. Remaining on the slides was evaporated at room temperature. Hybridized HPV DNA was visualized using a DNA Chip scanner (Scanarray 4000, GSI Lumonics, Ottawa, Canada).

Single infection HPV (must be at least one of 150 bp or 180 bp is detected) the results of the PCR and the \( \beta \)-globin (200 bp) This is all positive, marker spot all four detected and other 22 pairs spot one pairs of the its detected in the spot and the value of signal-to-background ratio (SBR) is more than 2.5.

Multiple infection HPV (must be at least one of 150 bp or 180 bp is detected) the results of the PCR and the \( \beta \)-globin (200 bp) This is all positive, marker spot all four detected and other 22 pairs spot two pairs of the its detected in the spot and the value of SBR is more than 2.5.

Other type were HPV (must be at least one of 150 bp or 180 bp is detected) the results of the PCR and the \( \beta \)-globin (200 bp) This is all positive, marker spot in four two SBR value of more than 4, with the exception of the marker spot 22 pairs of SBR is less than the spot value of 2.5.

The SBR values were HPV spot intensity / Background intensity. HPV amplicons can be hybridized with corresponding type-specific oligonucleotide probe and visualized on HPV DNA Chip slides as double positive spots (Fig. 1).

6. Statistical analysis

The level of statistical significance was defined as having a \( p \)-value of less than 0.05 or 0.01. Data were analyzed using PASW version 17.0 (SPSS Inc., Chicago, IL, USA). A chi-square test was used to check for the difference between data collected for different distribution values and the level of
Results

1. HPV prevalence in clinical patients for 2015 year

A total of 18.6% of the 5,614 participants tested positive for one or more of the HPV DNA genotypes, with 14.0% (784/5,614) testing positive for only HR-HPV, 3.1% (176/5,614) for only LR-HPV, and 1.5% (88/5,614) for both HR-HPV and LR-HPV (Table 1). Infections with multiple types of HPV were observed in 10.0% (105/1,046) of the HR-HPV positive and 2.3% (24/1,046) of LR-HPV. Among these participants, 12.3% (129/1,046) were infected with multiple (Table 1).

2. HPV genotype distribution single infection

The distribution of HPV genotypes (single) in the enrolled women is summarized in Table 2. Fifteen HR-HPV genotypes were found, the most common being HPV 16, detected in 20.2% of the 679 patients (Table 2). HPV 58 and HPV 52 were the next two most common HR-HPV genotypes. The 3 genotypes were present in 49.5% of all the HR-HPV infected women. Among LR-HPV infections, HPV 42 was the most common genotype, which was significantly more prevalent than HPV 6 and HPV 11.

3. HPV genotype distribution multiple infection

The distribution of HPV genotypes (multiple) in the enrolled women is summarized in Table 3. Multiple of HR-HPV genotypes were found, the most common being HPV 16/66 and HPV 56/58, detected in 8.4%, 7.3% of the 95 patients (Table 3). LR-HPV infections multiple type were HPV 40/44.

4. HPV infection as an age and sample type

The highest HR-, LR-HPV prevalence were observed in young women below 30-39 years of age, which was significantly higher than the 50~59 years aged groups (p<0.05), but was not very significantly different from the HPV prevalence in women older (Table 4). Those women between the ages of <60 years showed the lowest HPV prevalence. The cervices of the women infected with HPV were sample collected in the present study (Table 4). A ThinPrep sample type was highly positive the HPV infection finding for women infected with either HR-HPV or LR-HPV, observed in 65.2% and 14.4%.

Table 1. The prevalence of HPV genotype patterns

|          | Overall HPV | HR-HPV (+) |          | LR-HPV (+) |          |
|----------|-------------|------------|----------|------------|----------|
|          |             | Single     | Multiple |           | Single   | Multiple | Mixed infection* |
| Total    | 5,614       | 1,046      | 679      | 95         | 152      | 24       | 86               |
|          |             | (18.6)     | (12.1)   | (1.7)      | (2.7)    | (0.4)    | (1.5)            |
|          |             | 2          | 3        | 4          | 2        | 3        | 4                |
|          |             | (0.2)      | (0.02)   |            | (0.02)   |          |                  |

Values were n (%), Other type were 550 (10).
*Mixed infection of HR (high risk)– and LR (low risk)– HPV.
Discussion

The challenge of HPV DNA chip technique is to determine which assay would offer the most favorable balance between detection of pap smear and false positive test results generated by high assay sensitivity for detection of often inconsequential HPV infections. Clinical sensitivity is different from the analytical sensitivity of a given test system, as a test with a good clinical sensitivity usually has a higher cut-off for being positive than the analytical detection threshold that separates signal from noise. Therefore, clinical trials are needed to define the cut-off for the clinical sensitivity. Clinically validated HR-HPV DNA assays usable for primary HPV-based cervical cancer screening. For various assays, noninferior sensitivity and specificity for the outcome CIN2+ and sufficient intra- and interlaboratory reproducibility has been required by following the validation protocol. An

Table 2. The distribution of HPV single genotypes

| HPV genotype | n (%)     |
|--------------|-----------|
| HR-HPV       |           |
| Total        | 679 (100.0) |
| 16           | 137 (20.2)  |
| 18           | 42 (6.2)    |
| 31           | 16 (2.4)    |
| 33           | 23 (3.4)    |
| 35           | 17 (2.5)    |
| 39           | 24 (3.5)    |
| 45           | 10 (1.5)    |
| 51           | 59 (8.7)    |
| 52           | 73 (10.8)   |
| 56           | 49 (7.2)    |
| 58           | 126 (18.5)  |
| 59           | 14 (2.1)    |
| 66           | 43 (6.3)    |
| 68           | 45 (6.6)    |
| 69           | 1 (0.1)     |
| LR-HPV       |           |
| Total        | 152 (100.0) |
| 6            | 15 (9.9)    |
| 11           | 4 (2.6)     |
| 34           | 11 (7.2)    |
| 40           | 30 (19.7)   |
| 42           | 39 (25.7)   |
| 43           | 26 (17.1)   |
| 44           | 27 (17.8)   |

Values were only single detected HPV genotype.

Table 3. The frequency distribution of HPV multiple genotypes

| HR-HPV genotype | n (%)     | LR-HPV genotype | n (%)     |
|-----------------|-----------|-----------------|-----------|
| Total           | 66 (69.5) | Total           | 21 (87.5) |
| 16/18           | 2 (2.1)   | 34/42           | 3 (12.5)  |
| 16/35           | 4 (4.2)   | 40/42           | 3 (12.5)  |
| 16/58           | 2 (2.1)   | 40/44           | 13 (54.2) |
| 16/66           | 8 (8.4)   | 42/43           | 2 (8.3)   |
| 16/68           | 4 (4.2)   | each 1          | 3 (12.5)  |
| 18/51           | 3 (3.2)   | 18/52           | 2 (2.1)   |
| 18/56           | 2 (2.1)   | 18/58           | 2 (2.1)   |
| 40/44           | 13 (54.2) |
| 42/66           | 2 (2.1)   | 33/68           | 2 (2.1)   |
| 35/52           | 2 (2.1)   | 45/58           | 2 (2.1)   |
| 51/56           | 3 (3.2)   | 51/58           | 4 (4.2)   |
| 51/68           | 3 (3.2)   | 52/58           | 3 (3.2)   |
| 52/68           | 3 (3.2)   | 56/58           | 7 (7.3)   |
| 58/66           | 2 (2.1)   | 58/68           | 3 (3.2)   |
| each 1          | 29 (30.5) |

Table 4. Age and sample type-related prevalence of HR- and LR-HPV single genotypes

| Variable          | HR-HPV     | LR-HPV     | Total     |
|-------------------|------------|------------|-----------|
| Age               |            |            |           |
| >19               | 2 (0.2)    | 0 (0)      | 2 (0.2)   |
| 20 ~ 29           | 165 (19.9) | 36 (4.3)   | 201 (24.2) |
| 30 ~ 39           | 313 (37.7) | 70 (8.4)   | 383 (46.1) |
| 40 ~ 49           | 120 (14.4) | 31 (3.7)   | 151 (18.1) |
| 50 ~ 59           | 49 (5.9)   | 8 (1.0)    | 57 (6.9)  |
| <60               | 30 (3.6)   | 7 (0.9)    | 37 (4.5)  |
| Total             | 679 (81.7) | 152 (18.3) | 831 (100.0) |
| Sample type       |            |            |           |
| Cervical brushing | 133 (16.0) | 32 (3.9)   | 165 (19.9) |
| Formalin fixed tissue | 4 (0.5) | 0 (0)      | 4 (0.5)   |
| Thinprep          | 542 (65.2) | 120 (14.4) | 662 (79.6) |
important issue in the validation process of HPV tests is the origin of the samples and the status of the cervical cell specimen included in the series of cases with disease (CIN2+) or disease (≤CIN1) [20].

HPV testing in general is an established tool for the triage of borderline cytology results and national cervical cancer screening guidelines have been adapted accordingly in many countries [21]. Most widely-used commercial or in-house methods are mentioned in an historical perspective; however, some might have been missed accidentally.

Molecular detection of HPV DNA or RNA or protein even with its limitation is a powerful tool when evaluated properly in terms of clinical sensitivity and specificity. Method validation with proper reference materials and lab accreditation are necessary, they can guarantee for the analytical value of molecular HPV detection tests [22]. It has to be pointed out that, if considering the number of tests sold instead of the number of different tests manufactured in a given country, the would probably be different to compare CIN detection.

HPV assays: Hybrid capture 2 HPV DNA testing (Qiagen, Gaithersburg, MD, USA), Cobas HPV Test (Roche Diagnostics, Pleasanton, CA, USA), CLART HPV2 Assay Genomica, Madrid, Spain), and APTIMA HPV Test (Hologic/Gen-Probe, San Diego, CA, USA). Small differences in clinical characteristics were found for the four HPV assays in abnormal cytology aged ≥30 years. At younger ages, APTIMA was somewhat less sensitive for high-grade CIN than the three HPV DNA assays [23]. HR-HPV DNA detection in urine by the Trovagene HPV HR test in three different fractions from first void and initial stream urine was highly sensitive for the detection of CIN2+ in colposcopy patients. HR-HPV testing via non-invasive, simple, and highly acceptable urine sampling may be a viable method for cervical cancer screening [24].

The great majority of complete HPV diagnostic assays currently on the market are validated to be used for testing cervical scrapings only, and on top of that for scrapings collected by a single or usually up to no more than three different specimen collection devices. We urgently need an evaluation of the performance of as many commercial HPV tests as possible on a broader range of alternative clinical specimens: for example, other types of self-collected genital samples (different brushes, swabs and sponges, tampons), oral swabs, saliva, anal swabs, penile swabs, Guthrie-type filter paper [25].

High-risk HPV E6 protein inhibits expression of miR-34a through the p53-pathway to increase virus-infected cell survival and enhance cancer cell proliferation and metastasis. Undoubtedly, miR-34a is a highly promising biomarker of HPV-associated cancers [26].

A combined methylation assay for HPV 16, HPV 18, HPV 31, HPV 33 and four host genes has shown promise for triage of HPV positive women, but further studies are needed, particularly in comparison to established markers, to assess the value of HPV methylation for triage. If successful, a HPV methylation assay that covers the majority of carcinogenic types could provide combined HPV test results. These HPV genotyping and HPV methylation results in a single assay that would provide risk stratification for placing women in all but the highest risk groups [27].

Boers et al. [28] were identified new CIN2/3-specific methylation markers using genome-wide DNA methylation analysis. The diagnostic performance of our new methylation panel shows higher specificity. Methylation levels of 8/9 genes were significantly higher in carcinoma compared to normal scrapings. These 9 genes (ZSCAN1, ST6GALNAC5, ANKRD18CP, PAX2, CDH6, GFRA1, GATA4, KCNIP4, and LHX8) were selected for further diagnostic evaluation in cervical scrapings.

Moreover, as the other HPV genotype previously reports were rare in Korea [29,30], further studies are required with the HPV DNA chip test before the nationwide adoption of the vaccines. The HPV was a ubiquitous sexually transmitted infection, which often goes undiagnosed. Nevertheless, its wide prevalence has helped uncover some of the negative ramifications of infection with the virus. The role of HPV in the success of assisted reproduction is less clear-cut: several studies show a decreased pregnancy rate for intrauterine insemination and in vitro fertilization in women with HPV compared to controls, while other studies show no correlation [31].

Interventions with a systems-based approach have also been studied and are encouraged by the CDC as a mechanism
요 약

 인간 유두종 바이러스(HPV)에 의한 감염은 자궁경부암의 원인이다. HPV DNA의 세포 검사에서의 변화는 향후 더 도전적으로 발전을 가질 수 있다. HPV 유전자의 감염에 대한 새로운 HPV의 DNA (22종) chip 검사는 최근 한국에서 많이 도입되었다. 이 연구의 목적은 서울 지역에서 HPV 감염의 변이와 유전자형 분포를 알아보고자 하였다. 지난 2015년 한 해 동안 서울지역 종합병원 내원객을 대상으로 총 5,614 검체의 검사에서 HPV 유전자형은 1,596 (28.4%)에서 검출되었다. 이중 가장 자주 발견된 유전자형은 가진 집체(n=831) 중 고위험 HPV는 679 (42.5%), 저위험 HPV는 152 (9.5%)로 나타났다. 이에 본 연구는 종합 병원 방문자의 HPV 감염을 조사하였다. 이 연구 결과는 HPV 전국적으로 분포 및 백신의 도입을 안내하고, 이에 본 연구는 종합 병원 방문자의 HPV 감염을 조사하였다. 이에 본 연구는 종합 병원 방문자의 HPV 감염을 조사하였다. 이에 본 연구는 종합 병원 방문자의 HPV 감염을 조사하였다.
Thai women. Asian Pac J Cancer Prev. 2011;12:853-856.
20. Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K, Kocjan BJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015;21:817-826.
21. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-542.
22. Kroupis C, Vourlidis N. Human papilloma virus (HPV) molecular diagnostics. Clin Chem Lab Med. 2011;49:1783-1799.
23. Rebolj M, Lynge E, Ellegod D, Preisler S, Rygaard C, Bonde J. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology. Gynecol Oncol. 2014;135:474-480.
24. Senkomago V, Des Marais AC, Rahangdale L, Vibat CR, Erlander MG, Smith JS. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. J Clin Virol. 2016;74:26-31.
25. Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hers A, et al. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis. 2014;33:2005-2014.
26. Chen J, Zhao KN. HPV-p53-miR-34a axis in HPV-associated cancers. Ann Transl Med. 2015;3:331. doi: 10.3978/j.issn.
2305-5839.2015.09.39
27. Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016;138:2745-2751.
28. Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, et al. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics. 2016;8:29.
29. Lee YJ, Jung JH, Jung DY. The relationship between papanico-laou smear test and human papilloma virus DNA chip test in the uterine cervix. Korean J Clin Lab Sci. 2011;43:26-32.
30. Lee KO, Seong HS, Chung SJ, Jung NY, Lee HJ, Kim KT. Genotype frequency of human papillomavirus determined by PCR and DNA sequencing in Korean women. Korean J Clin Lab Sci. 2006;38:99-104.
31. Pereira N, Kucharczyk KM, Estes JL, Gerber RS, Lekovich JP, Elias RT, et al. Human papillomavirus infection, infertility, and assisted reproductive outcomes. J Pathog. 2015;2015:578423.
32. Park MS, Cho HW, Kim JG, Bae NY, Oh DS, Park HH. Genotype analysis of human papilloma virus infection in accordance with cytological diagnoses. Korean J Clin Lab Sci. 2015;47:39-45.
33. Kim GH, Kim SH, Park SY, Park SJ, Lin H, Ren Y, et al. Human papillomavirus prevalence and distribution according to age among Korean and Chinese women. Korean J Clin Lab Sci. 2015;47:259-266.